ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Elizabeth H.Z. Thompson Sells 16,558 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Elizabeth H.Z. Thompson sold 16,558 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the sale, the executive vice president owned 18,994 shares in the company, valued at approximately $496,313.22. This trade represents a 46.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $25.87 on Friday. The business has a 50 day moving average of $23.74 and a 200-day moving average of $23.23. The company has a market capitalization of $4.43 billion, a P/E ratio of 11.76, a P/E/G ratio of 18.41 and a beta of 0.80. ACADIA Pharmaceuticals Inc. has a 1 year low of $19.69 and a 1 year high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The business had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. Equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.39 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $37.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. Royal Bank Of Canada increased their price objective on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Canaccord Genuity Group raised their target price on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Stifel Nicolaus lifted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday. Thirteen analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.31.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 386 shares during the period. Meeder Asset Management Inc. acquired a new stake in ACADIA Pharmaceuticals during the 4th quarter worth about $26,000. Transamerica Financial Advisors LLC raised its position in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 1,005 shares in the last quarter. Federated Hermes Inc. raised its position in shares of ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 1,185 shares in the last quarter. Finally, Leonteq Securities AG bought a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth about $52,000. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.